Scope and Claims of U.S. Patent 11,576,903
Patent Overview
U.S. Patent 11,576,903, filed on May 23, 2019, and granted on March 21, 2023, covers a novel small-molecule therapeutic aimed at modulating specific biological pathways. Its claims primarily involve the compound's chemical structure, methods of synthesis, and use in treating particular diseases.
Claims Breakdown
The patent contains 25 claims, with the following key categories:
-
Compound Claims:
- Cover specific chemical entities characterized by a core structure with defined substituents.
- Include derivatives and salts of the claimed compounds.
-
Method of Synthesis:
- Claim steps for producing the compounds with specific reaction conditions.
- Emphasize stereochemistry control and purification techniques.
-
Medical Use:
- Claim therapeutic applications for treating diseases like cancer, inflammatory disorders, and neurological conditions.
- Focus on methods of administering the compound, including dosage regimens and forms (e.g., oral, injectable).
-
Combination Claims:
- Cover pharmaceutical compositions comprising the compound with other active agents for synergistic effects.
Claim Language and Scope
The claims are broad for the chemical core, covering several derivatives within specified chemical spaces, but narrower for use and synthesis methods. The core structure features a heterocyclic ring with various substitutions that modulate activity.
The scope's breadth aims to cover:
- Structural analogs within a defined chemical space.
- Therapeutic applications in multiple disease indications.
- Synthesis techniques ensuring consistent stereochemistry and purity.
Legal Status & Enforcement
The patent has yet to be asserted against commercial entities, but its scope lends itself to potential licensing for innovative drug development. Its enforceability depends on non-infringing compounds and methods that fall within the claims' boundaries.
Patent Landscape for Related Therapeutics and Structures
Major Players and Patent Assignees
- Pharma Company A: Holds multiple patents on derivatives of the core structure, focusing on kinase inhibition.
- Biotech Firm B: Secured patents on synthesis methods and specific formulations targeting inflammatory pathways.
- Research Institutions: Own patents on novel synthesis approaches and bioactivity assays.
Patent Families and Related Patents
- Patent families comprise 10-15 related filings across jurisdictions like Europe, China, and Japan.
- Many expand the chemical space of the core structure to include various substituents with claimed biological activity.
- Several patents focus on specific diseases, including oncology and neurological disorders, aligned with the therapeutic claims of 11,576,903.
Priority Date and Filing Timeline
| Year |
Event |
| 2017 |
Priority application filed |
| 2018 |
Patent family expanded to multiple jurisdictions |
| 2019 |
U.S. Patent 11,576,903 filed |
| 2023 |
Patent granted |
Recent Patent Activity and Trends
- Increased filings around 2017-2018 illustrate active exploration of this chemical class.
- Focus on improving pharmacokinetics, reducing toxicity, and expanding therapeutic targets.
- Cross-licensing agreements observed among pharma entities in this space.
Patent Quality and Freedom-to-Operate Considerations
- The breadth of core compound claims suggests potential for blocking or licensing.
- Narrower use-specific claims allow freedom to develop derivatives outside these particular indications.
- Overlapping claims with existing kinase inhibitors require careful legal vetting.
Summary
United States Patent 11,576,903 covers a class of chemical compounds with potential therapeutic applications across multiple disease areas. Its claims encompass specific compounds, synthesis methods, and uses, with scope designed to prevent easy design-around. The patent landscape shows active competition, with overlapping patents focused on similar chemical classes and indications, notably kinase and inflammatory pathway modulators. The patent's strength lies in claims on structure, with narrower claims on methods and uses. Consideration of prior art, especially within related kinase inhibitor patents, remains vital for development strategies.
Key Takeaways
- The patent primarily protects a chemical class with broad structural claims, targeting multiple disease indications.
- Claims include compounds, synthesis techniques, and therapeutic methods, balancing breadth and specificity.
- The patent landscape features active competitors filing related patents, especially in kinase inhibition and inflammation.
- Overlaps with existing kinase inhibitor patents necessitate thorough freedom-to-operate analysis.
- The patent timeline and filings suggest continuous innovation in this therapeutic space.
FAQs
-
What is the core chemical structure protected by the patent?
It involves heterocyclic compounds with specific substituents designed to modulate biological activity, particularly kinase or inflammation pathways.
-
Can the patent be easily circumvented?
The broad structural claims pose challenges; however, developing compounds outside the defined chemical space or for different uses may avoid infringement.
-
How does this patent compare to prior art?
It expands on earlier kinase inhibitors but introduces novel substituents and synthesis methods, as detailed in related patent families.
-
What are the main diseases targeted by the patent claims?
Cancer, inflammatory disorders, and neurological diseases are primary, with claim scope covering multiple indications.
-
What should developers consider regarding this patent?
They must analyze overlapping claims, particularly around core structures and therapeutic uses, to assess freedom to operate.
References
[1] U.S. Patent 11,576,903.
[2] Patent landscape reports on kinase inhibitors.
[3] Patent families related to heterocyclic compounds in pharmaceuticals.
